Results 51 to 60 of about 4,689 (214)

Insights from a six‐year hair drug analysis compendium in drug‐facilitated crimes involving vulnerable population cases

Journal of Forensic Sciences, EarlyView.
Abstract Hair analysis is a well‐established matrix in forensic toxicology, offering a valuable alternative or complement to traditional matrices in diverse contexts, including drug‐facilitated crimes (DFC), elder abuse, and accidental exposure in children.
Amandine Fort, Coralie Boudin, Hélène Eysseric‐Guerin, Virginie Scolan, François Paysant, Cloé Scherpereel, Mélissa Revet, Françoise Stanke‐Labesque, Théo Willeman   +8 more
wiley   +1 more source

Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial [PDF]

, 2017
Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of this study was to develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of LSD, iso-LSD, 2-oxo-3-hydroxy LSD (O-H-LSD)
Katharina M. Rentsch, Dolder, Patrick C., Matthias E. Liechti, Liechti, Matthias E., Rentsch, Katharina M., Patrick C. Dolder   +5 more
core   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

eLife, 2018
Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown ...
Katrin H Preller, Joshua B Burt, Jie Lisa Ji, Charles H Schleifer, Brendan D Adkinson, Philipp Stämpfli, Erich Seifritz, Grega Repovs, John H Krystal, John D Murray, Franz X Vollenweider, Alan Anticevic   +11 more
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Molecular docking and binding interaction between psychedelic drugs and human serum albumin

BioTechnologia, 2020
Drug-plasma protein interaction is a critical concern in monitoring drug circulation and drug-drug interactions. The present study aimed to investigate the interaction of psychedelic drugs such as lysergic acid diethylamide (LSD), dimethyltryptamine (DMT)
Hossein Khastar, Kobra Foroughi, Seyed Shahrokh Aghayan, Maryam Yarmohammadi, Moslem Jafarisani   +4 more
doaj   +1 more source

Classic psychedelics do not affect T cell and monocyte immune responses

Frontiers in Psychiatry, 2023
IntroductionClassic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, and neuronal damage.
Deborah Rudin, Deborah Rudin, Alexander Areesanan, Matthias E. Liechti, Matthias E. Liechti, Carsten Gründemann   +5 more
doaj   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Quel est l'impact potentiel du traitement du trouble lié à l’usage de l’alcool par le LSD : Une revue systématique d’essaies contrôlés randomisés, méthodes PRISMA

Cortica
Dans ce travail, l’objectif principal est d’explorer les effets et l’efficacité du diéthylamide de l'acide lysergique, plus communément connu sous le nom de LSD, dans le traitement du trouble lié à l’usage de l’alcool.
Maya Oberson
doaj   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source